Data / Research funding / Maryland / Meso Scale Diagnostics, LLC
Meso Scale Diagnostics, LLC: 6 NIH awards ($10.8M), fiscal years 2021 to 2026
Meso Scale Diagnostics, LLC in Rockville, MD is funded under 6 NIH awards ($10.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- MBWYUNWCFJ58
- State
- Maryland
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Multimarker surface signatures of human islet derived extracellular vesicles | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,815,725 | September 22, 2022 | May 31, 2027 | ROUTENBERG, DAVID AARON | reporter.nih.gov |
| Blood test to aid treatment decisions for perinatal asphyxiation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,467,152 | January 1, 2020 | September 30, 2025 | STENGELIN, MARTIN | reporter.nih.gov |
| Enabling isolation and characterization of single extracellular vesicles and their molecular contents using multi-marker surface signatures | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $1,980,644 | August 21, 2019 | June 30, 2024 | ROUTENBERG, DAVID AARON | reporter.nih.gov |
| Surface Signatures of Neuronal and Glial Extracellular Vesicles | NIH | National Institute of Mental Health | 2021 to 2022 | $1,790,866 | September 19, 2018 | July 31, 2025 | ROUTENBERG, DAVID AARON | reporter.nih.gov |
| A Flexible High-Throughput Immunological Assay to Support Next-Generation Influenza Vaccine Studies | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,679,190 | May 3, 2023 | April 30, 2026 | SIGAL, GEORGE B | reporter.nih.gov |
| HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $112,946 | March 15, 2017 | August 31, 2021 | SIGAL, GEORGE | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 1 | $691,014 | 0 | $0 |
| 2024 | 3 | $1,973,878 | 0 | $0 |
| 2023 | 3 | $2,750,100 | 0 | $0 |
| 2022 | 3 | $2,739,225 | 0 | $0 |
| 2021 | 4 | $2,692,306 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) | PAR-25-255 | NIH | 93.242 | November 5, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) | RFA-DK-27-125 | NIH | 93.847 | November 6, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Functional Target Validation for Alzheimer's Disease-Related Dementias | RFA-NS-26-034 | NIH | 93.853 | November 6, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) | RFA-DK-27-112 | NIH | 93.847 | November 9, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) | RFA-DK-27-139 | NIH | 93.847 | November 9, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required) | PAR-27-007 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1 award here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1 award here |
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) | RFA-NS-26-001 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) | RFA-NS-26-030 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional) | RFA-OD-27-009 | NIH | 93.310 | November 10, 2026 | Not listed | Same assistance listing 93.310 as 1 award here |
| Pilot Projects to Enhance the Human Virome Program (R03 Clinical Trials Not Allowed) | RFA-RM-27-024 | NIH | 93.310 | November 10, 2026 | $100,000 | Same assistance listing 93.310 as 1 award here |
| Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) | RFA-MH-27-150 | NIH | 93.242 | November 13, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.242 | November 16, 2026 | $50,000 | Same assistance listing 93.242 as 1 award here |
| Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required) | RFA-DK-27-122 | NIH | 93.847 | November 17, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) | PAR-25-052 | NIH | 93.853 | November 19, 2026 | Not listed | Same assistance listing 93.853 as 1 award here |
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) | PAR-25-226 | NIH | 93.242 | November 19, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.853 | November 23, 2026 | $375,000 | Same assistance listing 93.853 as 1 award here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.